From Yahoo's Profile: biz.yahoo.com
"Organogenesis, Inc. is a tissue engineering company that designs, develops and manufactures medical products containing living cells and/or natural connective tissue. The Company is the developer and manufacturer of the only mass-produced product containing living human cells to gain Food and Drug Administration (FDA) marketing approval. The Company's lead product, Apligraf, a cellular, bi-layered skin substitute, is FDA approved for the treatment of venous leg ulcers and diabetic foot ulcers; Novartis Pharma AG has global Apligraf marketing rights.
Organogenesis is leveraging its FortaFlex bioengineered collagen matrix technology into a family of products, and has recently achieved marketing clearance for its FortaPerm surgical sling and PuraPly wound dressing. The Organogenesis research pipeline includes the Vitrix living dermal replacement, a coronary vascular graft and a liver assist device."
Financial Summary
Organogenesis, Inc. designs, develops and manufactures medical therapeutics containing living cells and/or natural connective tissue. For the nine months ended 9/30/01, total revenues fell 13% to $7.6 million. Net loss before accounting change increased 52% to $22.6 million. Revenues reflect the absence of a $5 million milestone payment from Novartis related to diabetic foot ulcers. Loss also reflects $1.2 million in severance expenses.
--------------------------------------------------------------------------------
Officers
Albert Erani, 60, [Now Former] Chairman
Michael Sabolinski, M.D., 45, Pres, CEO, Director
John Arcari, 55, CFO, VP of Fin. and Admin., Sec., Treasurer
Nancy Parenteau, Ph.D., 47, Sr. VP of R&D and CSO
Paul DiCicco, 49, VP-Operations
AMEX:ORG - as of 3-Jan-2002
Price and Volume
52-Week Low on 18-Oct-2001 $3.75
Recent Price $5.09
52-Week High on 26-Feb-2001 $12.45
Beta 1.93
Daily Volume (3-month avg) 124.4K
Daily Volume (10-day avg) 118.0K
52-Week Change -37.6%
52-Week Change relative to S&P500 -28.6%
Share-Related Items
Market Capitalization $188.7M
Shares Outstanding 37.1M
Float 29.3M
Annual Dividend none
Last Split: factor 1.25 on 30-Apr-1998
Per-Share Data
Book Value (mrq) -$0.61
Earnings (ttm) -$0.86
Earnings (mrq) -$0.21
Sales (ttm) $0.26
Cash (mrq) $0.07
Valuation Ratios
Price/Book N/A
Price/Earnings N/A
Price/Sales (ttm) 19.45
Income Statements
Sales (ttm) $9.06M
EBITDA (ttm) -$24.0M
Income available to common (ttm) -$29.9M
Profitability
Profit Margin N/A
Operating Margin N/A
Fiscal Year
Fiscal Year Ends Dec 31
Most recent quarter 30-Sep-2001
Management Effectiveness
Return on Assets (ttm) -115.46%
Return on Equity N/A
Financial Strength
Current Ratio (mrq) 0.43
Debt/Equity N/A
Total Cash (mrq) $2.48M
Short Interest
As of 10-Dec-2001
Shares Short 1.95M
Percent of Float 6.7%
Shares Short
(Prior Month) 1.93M
Short Ratio 15.63
Daily Volume 125.0K |
